Intellia (NTLA) Posts $67.7M Revenue in FY 2025 Amid Loss

Intellia Therapeutics (NTLA) reported revenue of approximately $67.7 million for FY 2025, reflecting a year-over-year growth rate of nearly 17%. The company also faced a net loss of about $412.7 million for the same period. Omeros (OMER), transitioning to a commercial-stage entity, received FDA approval for Yartemlea in late 2025 but reported no revenue, and a net loss of approximately $3.4 million. Omeros holds $135.3 million in cash and $226.6 million in debt. The contrasting financial positions and stages could influence investor decisions in the biotech sector.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.